Pharmacokinetics of Melagatran and the Effect on Ex Vivo Coagulation Time in Orthopaedic Surgery Patients Receiving Subcutaneous Melagatran and Oral Ximelagatran: A Population Model Analysis - Eriksson, Ulf G; Mandema, Jaap W; Karlsson, Mats O; Frison, Lars; Olsson Gisleskog, Per; W??hlby, Ulrika; Hamr??n, Bengt; Gustafsson, David; Eriksson, Bengt I (Clinical pharmacokinetics, 2003)
Keywords: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines - administration & dosage; Azetidines - pharmacokinetics; Benzylamines; Biological and medical sciences; Biological Availability; Blood. Blood coagulation. Reticuloendothelial system; Body Weight; Coagulation monitoring; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; FARMACI; Glycine - administration & dosage; Glycine - analogs & derivatives; Glycine - blood; Glycine - pharmacokinetics; Humans; Medical sciences; Melagatran; Metabolic Clearance Rate; Partial Thromboplastin Time; pharmacodynamics; pharmacokinetics; Pharmacology. Drug treatments; PHARMACY; Postoperative Complications - prevention & control; Research and development; Sweden; Thromboembolism - prevention & control; Venous Thrombosis - prevention & control; Whole Blood Coagulation Time; Ximelagatran; Sweden; Human; Statistical analysis; Serine endopeptidases; Enzyme; Coagulation; Oral administration; Enzyme inhibitor; Thrombin; Anticoagulant; Prodrug; Route of administration; Biological activity; Melagatran; Peptidases; Orthopedic surgery; Ex vivo; Antithrombotic agent; Hydrolases; Subcutaneous administration; Activated clotting time; Mathematical model; Pharmacokinetics